Investing
Novartis’ Sandoz to generate additional $3 billion in net sales over next five years
© Reuters. FILE PHOTO: The company’s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann
LONDON (Reuters) – Novartis’ soon to be spun off generics division Sandoz is expected to expand its pipeline and generate an additional $3 billion in net sales over the next five years, the Swiss group said on Thursday.
The company intends to carve out Sandoz, which sells generics and biosimilars – cheap versions of biologic drugs made from living organisms – and generated about $9 billion in sales last year, to sharpen its focus on its patented prescription medicines in the second half of this year.
Read the full article here
-
Passive Income7 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Side Hustles7 days ago
How Your Body Language Can Help Win a Disagreement
-
Side Hustles6 days ago
How to Be Unapologetically You and Why It Matters
-
Side Hustles7 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Side Hustles6 days ago
With AI Magicx, It’s Like Getting an Entire Creative Team in One Money-Saving AI Tool
-
Investing7 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Investing5 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Side Hustles5 days ago
Mark Zuckerberg Is Now Second Richest Person in the World